Your browser is no longer supported. Please, upgrade your browser.
Settings
APHB AmpliPhi Biosciences Corporation daily Stock Chart
APHB [NYSE]
AmpliPhi Biosciences Corporation
Index- P/E- EPS (ttm)-19.42 Insider Own21.92% Shs Outstand8.28M Perf Week-2.79%
Market Cap8.13M Forward P/E- EPS next Y-11.20 Insider Trans0.00% Shs Float8.28M Perf Month14.76%
Income-22.70M PEG- EPS next Q-7.60 Inst Own2.40% Short Float6.68% Perf Quarter-69.79%
Sales0.20M P/S40.65 EPS this Y-23.70% Inst Trans-0.23% Short Ratio0.52 Perf Half Y-78.73%
Book/sh3.96 P/B0.25 EPS next Y-5.70% ROA-103.30% Target Price30.00 Perf Year-93.45%
Cash/sh0.27 P/C3.70 EPS next 5Y- ROE-161.80% 52W Range0.67 - 21.70 Perf YTD-77.69%
Dividend- P/FCF- EPS past 5Y10.30% ROI-217.40% 52W High-95.55% Beta2.83
Dividend %- Quick Ratio0.90 Sales past 5Y16.70% Gross Margin- 52W Low44.03% ATR0.12
Employees32 Current Ratio0.90 Sales Q/Q-72.60% Oper. Margin- RSI (14)51.64 Volatility15.35% 13.65%
OptionableNo Debt/Eq0.09 EPS Q/Q76.50% Profit Margin- Rel Volume0.57 Prev Close0.98
ShortableYes LT Debt/Eq0.00 EarningsAug 14 AMC Payout- Avg Volume1.06M Price0.96
Recom2.00 SMA201.17% SMA5011.04% SMA200-79.18% Volume112,176 Change-1.71%
Jul-10-17 08:00AM  AmpliPhi Biosciences Novel Approach to Treating Bacterial Infection Accesswire
Jul-05-17 06:50AM  AmpliPhi Biosciences to Present at Bacteriophage Therapy Workshop Sponsored by the FDA and NIH Business Wire +8.45%
Jun-28-17 05:00PM  APHB: New CEO to Lead New Strategic Focus Zacks Small Cap Research
Jun-14-17 06:50AM  AmpliPhi Biosciences Announces Presentation and Panel Participation at BIO International Convention Business Wire
May-31-17 04:05PM  AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer Business Wire
May-30-17 06:50AM  AmpliPhi Biosciences to Present at 7th Annual LD Micro Invitational Conference on June 6 Business Wire -6.88%
May-24-17 09:43AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-19-17 11:30AM  APHB: Changing Focus to Developing Personalized Phage Therapies Zacks Small Cap Research +11.76%
May-15-17 04:01PM  AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights Business Wire
May-11-17 06:50AM  AmpliPhi Biosciences to Hold Business Update Conference Call on May 15 Business Wire
May-10-17 05:29PM  AmpliPhi Biosciences Announces Closing of Public Offering Business Wire
May-05-17 11:05AM  AmpliPhi Biosciences Crumbles After Announcing Secondary Offering 24/7 Wall St. -58.62%
May-04-17 10:02PM  AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants Business Wire +62.92%
May-01-17 06:50AM  AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections Business Wire -8.68%
Apr-25-17 04:15PM  APHB: Looking to Follow-up on a Successful 2016 Zacks Small Cap Research -8.19%
06:50AM  AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference Business Wire
Apr-24-17 08:00AM  AmpliPhi Biosciences Review of Recent FDA Feedback and Drug Pipeline Accesswire +9.73%
Apr-17-17 09:00AM  AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal Business Wire
Apr-14-17 05:00PM  AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split Business Wire
Apr-04-17 06:50AM  AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences Business Wire
06:50AM  AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
Mar-31-17 01:04PM  AMPLIPHI BIOSCIENCES CORP Financials
Mar-29-17 12:54PM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube -7.87%
12:54PM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
10:24AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
Mar-27-17 05:06PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:55PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 10-K, Annual Report
04:11PM  AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights Business Wire
Mar-07-17 06:50AM  AmpliPhi Biosciences to Present at the 29th Annual ROTH Investor Conference Business Wire
Feb-23-17 06:50AM  AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman Business Wire
Feb-06-17 06:50AM  AmpliPhi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference Business Wire -6.46%
Feb-02-17 04:16PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Jan-30-17 06:50AM  AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer Business Wire
Jan-26-17 07:10AM  Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, and AmpliPhi Biosciences PR Newswire
Jan-09-17 08:32AM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
Jan-04-17 08:45AM  Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients Business Wire
Dec-22-16 12:50PM  ETFs with exposure to AmpliPhi Biosciences Corp. : December 22, 2016
Dec-19-16 05:11PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events
08:45AM  AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients Business Wire
Dec-09-16 12:03PM  ETFs with exposure to AmpliPhi Biosciences Corp. : December 9, 2016 -8.25%
Dec-05-16 04:32PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events
01:24PM  CORRECTING and REPLACING AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 Business Wire
Nov-18-16 01:00PM  APHB: Safety of AB-SA01 Firmly Established Following Phase 1 Trials -8.70%
Nov-17-16 05:03PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -28.87%
08:45AM  AmpliPhi Biosciences Announces Pricing of Public Offering of Common Stock and Warrants Business Wire
Nov-16-16 12:38PM  ETFs with exposure to AmpliPhi Biosciences Corp. : November 16, 2016 +7.78%
Nov-14-16 12:14PM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 -8.16%
08:47AM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
08:45AM  AmpliPhi Biosciences Announces Settlement of Pending Lawsuit Business Wire
Nov-10-16 05:27PM  AmpliPhi Biosciences Reports Third Quarter 2016 Financial Results and Provides Corporate Update Business Wire +6.80%
04:09PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 10-Q, Quarterly Report
Nov-01-16 08:45AM  AmpliPhi Biosciences Granted Small and Medium Enterprise Status by European Medicines Agency Business Wire
Oct-25-16 04:51PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events
09:20AM  AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis Business Wire
Oct-18-16 09:40AM  ETFs with exposure to AmpliPhi Biosciences Corp. : October 18, 2016
Oct-17-16 08:45AM  AmpliPhi Biosciences Appoints Dr. Carrie-Lynn Langlais Furr as Vice President of Regulatory Affairs and Program Management Business Wire
Sep-30-16 11:10AM  APHB: Early Signs of Efficacy Seen in Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis +10.14%
Sep-29-16 04:31PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Sep-20-16 09:54AM  AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients Business Wire
Sep-15-16 09:46AM  ETFs with exposure to AmpliPhi Biosciences Corp. : September 15, 2016
Sep-13-16 08:45AM  AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States Business Wire -8.24%
Sep-12-16 04:15PM  AmpliPhi Biosciences to Participate in Upcoming Conferences Business Wire
04:00AM  AmpliPhi Biosciences Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization Business Wire
Sep-01-16 08:01AM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events -6.47%
Aug-22-16 11:03AM  ETFs with exposure to AmpliPhi Biosciences Corp. : August 22, 2016
Aug-19-16 10:36AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q2, 2016 By the Numbers : August 19, 2016
Aug-15-16 04:28PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:16PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 10-Q, Quarterly Report
04:10PM  AmpliPhi Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q2 2016 AmpliPhi Biosciences Corp Earnings Release - Before Market Open
Aug-09-16 08:45AM  AmpliPhi Biosciences Confirms Clinical Trial Progress and Announces Upcoming Conference Call to Provide Corporate Update and Discuss Second Quarter 2016 Financial Results on August 15, 2016 Business Wire
Aug-04-16 02:38PM  ETFs with exposure to AmpliPhi Biosciences Corp. : August 4, 2016 -5.49%
08:45AM  AmpliPhi Biosciences Granted Japanese Patent Covering the Use of Phage Therapy to Resensitize Pseudomonas aeruginosa Infections to Antibiotics Business Wire
Aug-03-16 08:45AM  AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus Business Wire +51.67%
Jul-21-16 01:45PM  ETFs with exposure to AmpliPhi Biosciences Corp. : July 21, 2016
Jun-23-16 04:16PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V -6.43%
Jun-08-16 10:13AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -5.18%
Jun-02-16 08:45AM  AmpliPhi Biosciences to be Granted European Patent Covering the Use of Phage Therapy to Resensitize Bacterial Infections To Antibiotics Business Wire
Jun-01-16 08:51AM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity -27.48%
May-31-16 10:53PM  AmpliPhi Biosciences Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants Business Wire +39.11%
10:38AM  AmpliPhi Biosciences CEO to Discuss Novel Approaches to Fighting Drug-Resistant Pathogens in Panel at BIO International Business Wire
May-25-16 04:33PM  AmpliPhi Biosciences Corp.: Sudden move in price, will it continue?
May-24-16 08:36AM  AmpliPhi Biosciences Announces Start of First Phage Therapy Trial in U.S. Under IND Business Wire +51.53%
May-19-16 11:10AM  APHB: First Cohort Successfully Completed Treatment in Phase 1 Study of AP-SA01; Full Data in Third Quarter of 2016
May-12-16 04:33PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -7.18%
04:23PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 10-Q, Quarterly Report
04:15PM  AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q1 2016 AmpliPhi Biosciences Corp Earnings Release - Before Market Open
May-10-16 08:45AM  AmpliPhi Biosciences to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on May 13, 2016 Business Wire -7.20%
Apr-20-16 04:31PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
03:50PM  APHB: Preclinical Data Shows Broad Activity of AB-PA01 Against P. Aeruginosa Clinical Isolates; ECC With Intrexon Canceled
12:30PM  AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort Business Wire
Apr-18-16 09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
Apr-14-16 04:17PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Termination of a Material Definitive Agreement -16.46%
08:45AM  AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon Business Wire
Apr-12-16 04:15PM  AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients Business Wire
Apr-11-16 11:25AM  APHB: AmpliPhi Converts All Outstanding Series B Preferred Stock
Apr-08-16 04:21PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events, Financial Stateme
04:20PM  AmpliPhi Biosciences Announces Conversion of all Series B Redeemable Preferred Stock into Common Stock Business Wire
Apr-07-16 09:21AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: 2015 By the Numbers
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.